Retroperitoneal Fibrosis: Case Series of 20 Patients
Science Journal of Public Health
Volume 5, Issue 4, July 2017, Pages: 294-300
Received: Mar. 29, 2017; Accepted: Apr. 12, 2017; Published: Jun. 13, 2017
Views 1584      Downloads 42
Authors
Kaddouri Said, Department of Internal Medicine, Ibn Sina Military Hospital, Marrakesh, Morocco
Ghoundale Omar, Department of Urology, Ibn Sina Military Hospital, Marrakesh, Morocco
Chahbi Zakaria, Department of Internal Medicine, Ibn Sina Military Hospital, Marrakesh, Morocco
Essadi Ismail, Department of Medical Oncology, Ibn Sina Military Hospital, Marrakesh, Morocco
Qacif Hassan, Department of Internal Medicine, Ibn Sina Military Hospital, Marrakesh, Morocco
Zamraoui Nadir, Department of Nephrology, Ibn Sina Military Hospital, Marrakesh, Morocco
Zyani Mohamed, Department of Internal Medicine, Ibn Sina Military Hospital, Marrakesh, Morocco
Article Tools
Follow on us
Abstract
Retroperitoneal fibrosis (RPF) is a rare disease. The objective of this paper is to study the prevalence, clinical, biological and radiological aspects of the RPFand to specify its therapeutic modalities. This study provides descriptive evidence for a series of 20 patients with RPF. We conducted a retrospective study of cases of RPF diagnosed in the Urology and Internal Medicine departments of the Ibn Sina Military Hospital in Marrakech over a five-year period from July 2010 to December 2015. The positive diagnosis of RPF was retained either on the basis of a histological analysis from a biopsy fragment or, in the absence of histological evidence, by the detection on a scan of an infiltrate or "sleeve" Regular and homogeneous tissue density, perivascular topography, surrounding the abdominal aorta, more or less extended to the iliac vessels and able to take the contrast after injection. They were 15 men and 5 women with an average age of 53 years with extremes of 41 to 74 years. Almost all patients had mainly lumbar and abdominal pain. An inflammatory syndrome existed in all cases and renal insufficiency in 15 cases. Radiological investigations showed unilateral or bilateral hydronephrosis in 16 cases. RPF was idiopathic in 14 patients. Secondary forms were present in 6 patients (three atheromatous diseases, one gastric tumor, one case associated with Riedel's thyroiditis and one case of systemic fibrosis associating RPF, Riedel's thyroiditis and liver fibrosis). The treatment consisted of corticosteroids in 19 cases, surgery in 17 cases associated with corticosteroid therapy or even immunosuppressant in the case of steroid-dependence. Two deaths were observed in this series; one of these two patients had developed cervix carcinoma with pleural and peritoneal metastases after 5 years of immunosuppressive therapy. The second died due to the complications of his gastric neoplasm. The general characteristics of patients included are similar to the other series of the literature. The frequency of secondary forms seems to be underestimated, hence the value of a rigorous etiological investigation. The therapeutic strategy and the use of the cortisone saving treatments should be specified by randomized therapeutic trials. The prognosis is generally good; however, the possibility of recurrences, the incidence of which is greater during the first five years, requires prolonged clinical, biological and radiological monitoring.
Keywords
Retroperitoneal Fibrosis, Atheroma, Neoplasm, Vasculitis, Riedel's Thyroiditis, Corticosteroids
To cite this article
Kaddouri Said, Ghoundale Omar, Chahbi Zakaria, Essadi Ismail, Qacif Hassan, Zamraoui Nadir, Zyani Mohamed, Retroperitoneal Fibrosis: Case Series of 20 Patients, Science Journal of Public Health. Vol. 5, No. 4, 2017, pp. 294-300. doi: 10.11648/j.sjph.20170504.13
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Augusto Vaglio, Carlo Salvarani, Carlo Buzio. Retroperitoneal fibrosis The Lancet, Vol. 367 January 21, 2006 p 241-251
[2]
Chauveau D, et al. Retroperitoneal fibrosis: recent clinical and physiopathological facts. Seminar of uro-nephrology, 1997, 13th Series.
[3]
Lioger B, et al. Fibrose rétropéritonéale de l’adulte: analyse descriptive et évaluation de la pertinence des examens complémentaires réalisés à visée diagnostique à partir d’une série rétrospective multicentrique de 77 cas. Rev Med Interne (2015).
[4]
Meier P, et al. RPF, an unrecognized inflammatory disease. Clinical observations and review of the literature. Nephrology Vol. 24, No. 4 2003, pp. 173-180.
[5]
Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J. Urol. 1948 June; 59 (6): 1072-9.
[6]
Mezghani S, et al. Imaging of retroperitoneal and pelvic fibroses. Encycl.Med.Chir., Radiodiag.Urol.Gyneco. 2003; 34-290-A-10, 16p.
[7]
Keehn AY, et al. Robotic ureterolysis for relief of ureteral obstruction from retroperitoneal fibrosis. Urology. 2011 June 77 (6): 1370-4.
[8]
Vaglio A, et al. Prednisone versus tamoxifen in patients with idiopathic RPF: an open label randomized controlled trial. Lancet. 2011 Jul 23; 378 (9788): 338-46.
[9]
Scheel PJ Jr, Feeley N. RPF: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore). 2009 Jul; 88 (4): 202-7.
[10]
Lugosi M, et al. RPF diagnostic strategy, associated pathologies and long-term follow-up of a French cohort. The J of Internal Med 34 (2013) 591-599.
[11]
Van Bommel. Retroperitoneal fibrosis. JULY 2002, Vol. 60, No. 6.
[12]
Wong C, et al. Localized idiopathic retroperitoneal fibrosis mimicking primary obstructive megaureter in a child. J.Urol. 2000; 163: 1913-1914.
[13]
Gallais Seresal, et al. RPFI: long-term progression of renal prognosis in a retrospective multicenter series of 30 cases. International J of Med, 33S (2013) A28-A89.
[14]
Paul J Scheel Jr, Nancy Feeley. Retroperitoneal fibrosisRheum Dis Clin N Am 39 (2013) 365-381.
[15]
Pipitone N, et al. Retroperitoneal fibrosis. Best Practice & Research Clinical Rheumatology 26 (2012) 439–448.
[16]
University College of Teachers of Nephrology. Nephrology: Chapter 01, 6th Edition
[17]
Stone JH, Zen Y, Deshpande V. IgG4-related disease. N. Engl. J. Med. 2012 Feb 9; 366 (6): 531-51
[18]
De Luca S, Terrone C, et al. Aetiopathogenesis and treatment of idiopathic retroperitoneal fibrosis. Ann Urol, 1998; 32, No. 3: 153-159.
[19]
Shacahf Shiber, et al. RPF: case series of five patients and review of the literature. Rev. bras. reumatol. 2016;56(2):101–104
[20]
Doolin EJ, Goldstein H, Kessler B, et al. Family retroperitoneal fibrosis. J. Pediatr Surg 1987; 22 (12): 1092-4.
[21]
Hatsiopoulou O, Irving S, Sharma SD. Retroperitoneal fibrosis in two brothers J. Urol 2001; 16: 182.
[22]
Baker LRI, et al. Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br. J Urol 1988; 60: 497-503.
[23]
Koep L, Zuidema GD. The clinical significance of retroperitoneal fibrosis.Surgery 1977; 81: 250-57.
[24]
The Guyader S. The RPF: about 46 observations. Thesis, Lyon I, 1992, No. 92, LY01M047
[25]
Wagenknecht L, Hardy J. Value of various treatment for retroperitoneal fibrosis. Eur. Urol 1981 (7) 193-200.
[26]
Eric F.H. van Bommel, et al. Long-Term Renal and Patient Outcome in Idiopathic RPF Treated With Prednisone Am. J. Kidney 49: 615-625.
[27]
Garroustre C. et al. RPF retrospective study in 14 patients. Journal of nephrology, 2012, p: 341.
[28]
Kaaroud El Jeri H, et al. Retroperitoneal fibrosis Presse Med 2005; 34: 213-17.
[29]
Chauveau D, et al. FRP: recent clinical and physiopathological facts. Seminar of uronephrology Pitié Salpêtrière, 1997; 13th Series; MED Edition.
[30]
Khan MF, Peltier AP, Meyer O, Piette JC. Idiopathic systemic fibrosis. Flammarion Medicine-Science. Paris 1991: 1115-36.
[31]
Cassim F, et al. An atypical cause of retroperitoneal fibrosis: Case report and literature review. African Journal of Urology (2017) 23, 62–65.
[32]
Lepor H, Walch P. Idiopathic Retroperitoneal Fibrosis The Journal of Urology 1979 Vol. 122, 1-6.
[33]
Vivas I, Nicolas A, Velazquez P. Retroperitoneal fibrosis: typical and atypical manifestations. Br.J.radiol. 2000; 73: 21-222.
[34]
Degesys GE, Dunnick NR, et al. Retroperitoneal fibrosis: Use of CT in distinguishing among possible causes. AJR 1986; 146: 57-60.
[35]
Triantopoulou C, Rizos S, Bourli A, et al. Localized unilateral perirenal fibrosis: CT and MRI appearances. Eur Radiol 2002; 12: 2743-6.
[36]
Fernando A, et al. [18F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. Eur Urol (2016).
[37]
Moroni G. et al. The value of (18) F-FDG PET / CT in the assessment of active idiopathic RPF. Eur J Nucl Med Mol Imag 2012: 39: 1635-42.
[38]
Cotsamire D, et al. Clinical parameters and therapeutic outcome in patients with idiopathic RPF. Arthritis Rheum 1991; 34: R34-R8.
[39]
Eric F.H. van Bommel,et al.Long-Term Renal and Patient Outcome in Idiopathic Retroperitoneal Fibrosis Treated With Prednisone.American Journal of Kidney Diseases, Vol 49, No 5 (May), 2007: pp 615-625
[40]
Renzo Marcolongo,et al. Immunosuppressive Therapy for Idiopathic Retroperitoneal Fibrosis: A Retrospective Analysis of 26 Cases. THE AMERICAN JOURNAL OF MEDICINE 2004;Volume 116:194-197
[41]
Bréchignac X, de Wazières B, Desmurs H, et al. New medical treatments of idiopathic systemic fibroses. Rev Med Interne 1997; 18: 967-71.
[42]
Augusto Vaglio,et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fi brosis: an open-label randomized controlled trial. Lancet 2011; 378: 338–46
[43]
Van Bommel E.F.H., et al. Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. European Journal of Internal Medicine 24 (2013) 444–450.
[44]
François Desgrandchamps, Alain Le Duc. Provisional or definitive urinary excretion by endoscopic or percutaneous route. EMC, 41-140 (1994)
[45]
Cooksey G, Powell PH, Singh M, Yeates WK. Idiopathic RPF: A long-term review after surgical treatment. Br J Urol 1982; 54: 628-31.
[46]
Tiptaft RC, Costello AJ, Paris AM, Blandy JP. The long-term follow-up of idiopathic retroperitoneal fibrosis. Br J Urol 1982; 54: 620-3.
[47]
Tanaz A. Kermani, et al. Idiopathic Retroperitoneal Fibrosis: A Retrospective Review of Clinical Presentation, Treatment, and Outcomes. Mayo Clin Proc. 2011;86(4):297-303.
[48]
Biserte J, Mokbel K, et al. Treatment of FRPI Uterolysis or Corticotherapy? Annals of Urology 1984, 18 (5), 304-30.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186